bicyclo<4.2.0>oct-2-en-7-one | 31996-68-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: bicyclo<4.2.0>oct-2-en-7-one
• 英文别名: bicyclo[4.2.0]-oct-2-en-7-one；Bicyclo[4.2.0]oct-2-en-7-one
• CAS: 31996-68-6
• 化学式: C₈H₁₀O
• 分子量: 122.167
• InChiKey: JKLZCTYQZFXPSW-UHFFFAOYSA-N

物化性质

• 沸点：
  205.1±19.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bicyclo<4.2.0>oct-2-en-7-one 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 正丁基锂 、 硫酸 、 三氟化硼乙醚 、 dimsylsodium 、 sodium carbonate 、 对甲苯磺酸 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 、 苯 为溶剂， 反应 49.33h， 生成 butanoic acid, 4-[(1S,2S,3R,6S)-2-[(3S)-3-cyclohexyl-3-hydroxy-1-propynyl]-3-hydroxybicyclo[4.2.0]oct-7-ylidene]-(4Z)
  参考文献：
  名称：

  Potent prostacyclin analogs based on the bicyclo[4.2.0]octane ring system

  摘要：

  DOI：

  10.1021/jo00389a038
• 作为产物：
  描述：

  8,8-dichlorobicyclo<4.2.0>oct-2-en-7-one 在 溶剂黄146 、 锌 作用下， 以89%的产率得到bicyclo<4.2.0>oct-2-en-7-one
  参考文献：
  名称：

  7-d-和8-d-双环[4.2.0]oct-2-烯的热反应

  摘要：

  双环[4.2.0] oct-2-ene 和7-d 和8-d 类似物在300 摄氏度的气相热反应已通过GC 和2 H 核磁共振光谱分析动力学遵循。与双环 [3.2.0]hept-2-ene 和氘标记类似物所表现出的转化模式相比，没有看到由 C1-C6 键断裂引发的反应，C8 处的差向异构化比 [1,3] 快得多导致双环[2.2.2] oct-2-ene 的位移，并且[1,3] 碳迁移与反转与迁移与保留的速率常数之比约为1.4。C1-C8 的均裂得到构象灵活的双自由基中间体，该中间体具有相对较长的寿命和多种进一步反应选择（C1-C8 的重新形成，有或没有净差向异构化，裂解为 1,3-环己二烯和乙烯，迁移到具有反转或保留的原始 C3）与观察结果非常吻合。显然，轨道对称控制不控制 [1,3] σ 碳位移的立体化学。

  DOI：

  10.1021/ja0636035

文献信息

• Preparation of 15-deoxy-16-hydroxyprostaglandins
  申请人：Miles Laboratories, Inc.

  公开号：US04132738A1

  公开（公告）日：1979-01-02

  Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## SUCH THAT A BICYCLOALKYL OR BICYCLOALKENYL COMPOUND IS FORMED, WHEREIN M AND N ARE INTEGERS HAVING A VALUE FROM 0 TO 3, P IS AN INTEGER HAVING A VALUE FROM 0 TO 4 AND Q IS AN INTEGER HAVING A VALUE OF FROM 1 TO 4 AND WHEREIN THE DOUBLE BOND OF SUCH BICYCLOALKENYL IS IN THE M, N, P, OR Q BRIDGE; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. Pge.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3 R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

  具有结构式##STR1##的PGE.sub.1的类似物，其中J是R-羟甲亚甲基或S-羟甲亚甲基；R.sub.1是氢；R.sub.2是氢或与R.sub.4一起是2到3个碳原子的亚甲基链，形成包括5到6个碳原子的环烷基；R.sub.3是氢或甲基，或与R.sub.4一起是2到5个碳原子的亚甲基或低烷基化亚甲基链，形成包括4到7个碳原子的环烷基或低烷基化环烷基，或与R.sub.4一起是具有式子的双环烷基或双环烯基基团：##STR2##形成双环烷基或双环烯基化合物，其中M和N是具有值从0到3的整数，P是具有值从0到4的整数，Q是具有值从1到4的整数，且此类双环烯基的双键位于M、N、P或Q桥上；R.sub.4是氢或甲基，或与R.sub.2或R.sub.3一起形成如上定义的环烷基或双环烷基或双环烯基，或与R.sub.5一起是3到5个碳原子的亚甲基链，形成包括4到6个碳原子的环烷基；R.sub.5选自由氢、具有1到3个碳原子的直链烷基或与R.sub.4一起形成如上定义的环烷基；R.sub.6是氢或具有1到3个碳原子的直链烷基。上述结构的Pge.sub.1酯类似物，限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、低烷基化环烷基、双环烷基或双环烯基的结构也被披露。这些前列腺素类似物在体内选择性地产生支气管扩张并减少胃分泌。还披露了制备这些类似物以及合成这些类似物所需的起始物料的方法。
• Process and intermediates for the synthesis of the enantiomers of bicyclo(4.2.0)oct-2-en-7-one and derivatives and for the synthesis of bicyclo(4.2.0)octane derivatives
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0257610A3

  公开（公告）日：1989-05-24

  The enantiomers of formulas are prepared in a sequence starting from the racemic compound of formulawherein X is hydrogen or bromo when Y is bromo, or X is chloro when Y is chloro.The key step of this process involves a microbial reduction of the compound of formula (3) to give a ketone and an alcohol of high enantiomeric purity. The compounds of formulas (1) and (2) are intermediates for the preparation of certain bicyclo[4.2.0]octane derivatives.

  这些公式的对映异构体是从公式的消旋化合物开始的顺序制备的，其中X为氢或溴，Y为溴时，或者X为氯，Y为氯时。这个过程的关键步骤涉及将公式（3）的化合物进行微生物还原，得到高对映纯度的酮和醇。公式（1）和（2）的化合物是制备某些双环[4.2.0]辛烷衍生物的中间体。
• Compound And Method
  申请人：University of Bristol

  公开号：US20150158837A1

  公开（公告）日：2015-06-11

  A compound of formula (I): (I) wherein Y is, Z is OR 10 , NR 11 R 11 SR 11 , S(0)R 11 S0 2 R 11 , R 10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO—R 11 , or a protecting group, and R 11 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl; a process for making a compound of formula (I); and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I). wherein Y is

  公式(I)的化合物：(I)其中Y是，Z是OR10，NR11R11SR11，S(0)R11S02R11，R10是H，可选择地取代的烷基，可选择地取代的环烷基，可选择地取代的烯基，可选择地取代的炔基，可选择地取代的芳基，可选择地取代的杂芳基，可选择地取代的杂环烷基，CO—R11，或保护基，而R11可选择地取代的烷基，可选择地取代的环烷基，可选择地取代的烯基，可选择地取代的炔基，可选择地取代的芳基，可选择地取代的杂芳基，可选择地取代的杂环烷基，或者烷氧基；制备公式(I)的化合物的方法；以及利用公式(I)的化合物制备前列腺素或前列腺素类似物的方法。其中Y是
• [EN] COMPOUND AND METHOD<br/>[FR] COMPOSÉ ET PROCÉDÉ
  申请人：UNIV BRISTOL

  公开号：WO2013186550A1

  公开（公告）日：2013-12-19

  A compound of formula (I): (I) wherein Y is, Z is OR10, NR11R11 SR11, S(0)R11 S02R11, R10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO-R11, or a protecting group, and R11 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl; a process for making a compound of formula (I); and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I).

  公式（I）的化合物：（I）其中Y是，Z是OR10，NR11R11 SR11，S（0）R11 S02R11，R10是H，可选地取代的烷基，可选地取代的环烷基，可选地取代的烯基，可选地取代的炔基，可选地取代的芳基，可选地取代的杂环芳基，可选地取代的杂环烷基，CO-R11或保护基，R11是可选地取代的烷基，可选地取代的环烷基，可选地取代的烯基，可选地取代的炔基，可选地取代的芳基，可选地取代的杂环芳基，可选地取代的杂环烷基或烷氧基；制备公式（I）的化合物的方法；以及使用公式（I）的化合物制备前列腺素或前列腺素类似物的方法。
• Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04608388A1

  公开（公告）日：1986-08-26

  Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension, and atherosclerosis are compounds depicted in formulas (1), (2), and (3): ##STR1## wherein: n is 2 or 3; R.sub.1 is CH.sub.2 OH, CHO, CO.sub.2 R or CO.sub.2 H; R.sub.2 is hydrogen or methyl; and R.sub.3 is linear or branched alkyl having 5-10 carbon atoms, ##STR2## optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen, in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is ##STR3## in which each R.sub.4 is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof.

  以下是用于治疗心血管疾病如血栓形成、高血压和动脉粥样硬化的化合物，其化学式为（1）、（2）和（3）的化合物：##STR1## 其中：n为2或3；R.sub.1为CH.sub.2 OH、CHO、CO.sub.2 R或CO.sub.2 H；R.sub.2为氢或甲基；R.sub.3为具有5-10个碳原子的直链或支链烷基，##STR2## 可选择地取代较低的烷基、较低的烷氧基、三氟甲基或卤素，其中a为0、1或2；b为3-7；m为1或2；R为##STR3## 其中每个R.sub.4独立地为氢或具有1-6个碳原子的较低烷基，并且其药学上可接受的、无毒的盐和酯。